{
    "id": "correct_subsidiary_00103_1",
    "rank": 45,
    "data": {
        "url": "https://talemhealth.digitellinc.com/live/119/page/928",
        "read_more_link": "",
        "language": "en",
        "title": "Oncology Congress",
        "top_image": "https://akamai-opus-nc-public.digitellcdn.com/assets/img/talemhealth/events/119/",
        "meta_img": "https://akamai-opus-nc-public.digitellcdn.com/assets/img/talemhealth/events/119/",
        "images": [
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/65065232a3c0257e184a9c09fa450c977686a5c39cb2e5229a1ea43a2c8ddd77.png.webp",
            "https://assets.prod.dp.digitellcdn.com/api/services/imgopt/fmt_webp/akamai-opus-nc-public.digitellcdn.com/uploads/talemhealth/redactor/6a6a68557836e1bec571bbd8f545f4c1baa9daeb88889a423dedb7349bf69d8a.png.webp"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://talemhealth.digitellinc.com/assets/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://talemhealth.digitellinc.com/live/119/page/928",
        "text": "Saturday, April 13, 2024 | Live CME/CE Conference Broadcast starts at 8:00 AM CT\n\nHOW TO CLAIM CREDIT\n\nIn order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:\n\nStep 1: Log In\n\nAccess the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.\n\nIf you do not know your password, follow the link to reset it.\n\nStep 2: Complete Evaluation(s)\n\nClick the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.\n\nStep 3: View and Print Certificate(s)\n\nAfter you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.\n\nFor Pharmacists: Upon completion of the online evaluation(s), your credits will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluations and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.\n\nPARP Inhibitors in Prostate Cancer: Practical Application of Recent Advances\n\nto Ensure Equitable Care in Rural and Underserved Populations\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nDescribe the mechanism of action and clinical rationale for using PARP inhibitors in the management of metastatic castration-resistant prostate cancer (mCRPC)\n\nEvaluate recent clinical trial data for novel and emerging PARP inhibitor therapy for mCRPC\n\nIntegrate the latest data and expert guidance on PARP inhibitor therapy to develop personalized treatment plans for patients with mCRPC\n\nEmploy interprofessional strategies to overcome barriers and support equitable prostate cancer care in rural and underserved populations\n\nFACULTYNeeraj Agarwal, MD, FASCO\n\nProfessor of Medicine\n\nSenior Director of Clinical Research\n\nDirector, Genitourinary Oncology Program\n\nNCICCC Huntsman Cancer Institute, University of Utah\n\nSalt Lake City, UT\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-028-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTEREST\n\nTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFaculty Neeraj Agarwal, MD, FASCO, has disclosed the following relevant financial relationships: contracted research (awarded to institution) from Arvinas, Inc., Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, Bristol Meyers Squibb, Calithera Biosciences, Celldex Therapeutics, Inc., CRISPR Therapeutics, Eisai Co., Ltd., Eli Lilly and Company, EMD Serono, Inc., Exelixis, Inc., Genentech, Inc., Gilead Sciences, Inc., GSK, Immunomedics, Inc. (now Gilead Sciences, Inc.), Janssen Pharmaceuticals, LAVA Therapeutics, Merck & Co., Inc., Nektar Therapeutics, Neoleukin Therapeutics, Inc., Novartis Pharmaceuticals, ORIC Pharmaceuticals, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, and TRACON Pharmaceuticals, Inc.\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USE\n\nThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nOptimizing Risk Stratification and Management of Myelodysplastic Syndrome:Strategies for Improving Equitable Access to Care in Rural and Underserved Communities\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported through an educational grant from Bristol Myers Squibb.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nUtilize appropriate diagnostic techniques and risk stratification to determine optimal management strategies for patients with myelodysplastic syndrome (MDS)\n\nApply patient-centered strategies for improving the management and monitoring of patients with MDS\n\nIntegrate current evidence into decisions about first-line treatment of anemia in patients with lower-risk MDS who have not previously been treated with erythropoietin-stimulating agents and may require blood transfusions\n\nEvaluate the safety and efficacy of new and emerging therapies for MDS\n\nEmploy evidence-based strategies for improving access to care and collaborative management of patients with MDS who reside in rural and underserved communities\n\nFACULTY Rami S. Komrokji, MD\n\nVice Chair, Department of Malignant Hematology\n\nSection Head, Leukemia and MDS\n\nMoffitt Cancer Center\n\nProfessor, Department of Oncologic Sciences\n\nUniversity of South Florida\n\nTampa, FL\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-033-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTERESTTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFaculty Rami S. Komrokji, MD, has disclosed the following relevant financial relationships: speakers’ bureau/advisory board for AbbVie, Inc., Bristol Myers Squibb, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, PharmaEssentia, Rigel Pharmaceuticals, Inc., Servier, Sobi, and Sumitomo Pharma Co., Ltd.; research/grant support from Bristol Myers Squibb; consultant for Geron, Janssen Pharmaceuticals, and Sumitomo Pharma Co., Ltd.\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USE\n\nThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nGastric and Gastroesophageal Cancer: Navigating the Evolving\n\nTreatment Landscape to Optimize Care and Advance Health Equity\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nExplain the role of biomarkers in gastric/gastroesophageal (GEJ) cancers to guide diagnosis and treatment decisions\n\nDescribe the mechanism of action of emerging systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers\n\nEvaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers\n\nImplement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers\n\nFACULTYYelena Y. Janjigian, MD\n\nProfessor of Medicine\n\nWeill Cornell Medical College\n\nChief Attending, Gastrointestinal Oncology Service\n\nMemorial Sloan Kettering Cancer Center\n\nNew York, NY\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-029-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTEREST\n\nTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFacultyYelena Y. Janjigian, MD, has disclosed the following relevant financial relationships: advisory board member/consultant for AbbVie, Inc., AmerisourceBergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks, Inc.; speakers’ bureau for AbbVie, Inc., Amerisource Bergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Lynx Health, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks Inc.; research/grant support from Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Arcus Biosciences, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc./Roche, Inspirna, Merck & Co., Inc., and Transcenta; stock ownership interest in Inspirna.\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nAdvances in HER2-Mutant Non-Small Cell Lung Cancer (NSCLC):\n\nOptimizing Outcomes in Rural and Underserved Communities\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nApply guideline-recommended genomic testing to identify actionable driver mutations, including HER2 activating mutations, and inform treatment decisions in patients with NSCLC\n\nIntegrate the latest clinical evidence on HER2-directed agents into treatment plans for patients with HER2-altered advanced NSCLC\n\nEmploy collaborative strategies for the prevention and management of common and serious treatment-related adverse events in patients with NSCLC receiving HER2-directed agents\n\nFACULTYRebecca S. Heist, MD, MPH\n\nAssociate Professor of Medicine\n\nHarvard Medical School\n\nLee Albright and Nile Albright MD Endowed Chair, Clinical Cancer Research\n\nMassachusetts General Hospital Cancer Center\n\nBoston, MA\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-031-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTEREST\n\nTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFacultyRebecca S. Heist, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., CLaiM Therapeutics, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi; contracted research (awarded to institution) for AbbVie, Inc., Agios Pharmaceuticals, Corvus Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly and Company, Erasca, Inc., Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc. (now Bristol Myers Squibb).\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USE\n\nThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nTROP2-Targeted Antibody-Drug Conjugates in NSCLC:An Update for Oncologists who Serve Patients in Rural and Underserved Communities\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nDescribe the role of TROP2 as a potential therapeutic target in patients with non-small cell lung cancer (NSCLC) and the rationale for using antibody-drug conjugates to target this marker\n\nEvaluate the current safety and efficacy data related to TROP2-directed antibody-drug conjugates for the treatment of NSCLC\n\nImplement strategies to address disparities in lung cancer care, testing, and treatment in rural and underserved communities\n\nFACULTYRebecca S. Heist, MD, MPH\n\nAssociate Professor of Medicine\n\nHarvard Medical School\n\nChair, Clinical Cancer Research\n\nMassachusetts General Hospital Cancer Center\n\nBoston, MA\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-030-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTERESTTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFacultyRebecca S. Heist, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., CLaiM Therapeutics, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi; contracted research (awarded to institution) for AbbVie, Inc., Agios Pharmaceuticals, Corvus Pharmaceuticals, Daiichi Sankyo, Inc., Erasca, Inc., Eli Lilly and Company, Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc. (now Bristol Myers Squibb).\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USE\n\nThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nImproving Equity in Hepatocellular Carcinoma Care:\n\nIntegrating Evolving Treatment Approaches in Rural and Underserved Communities\n\nProvided by Talem Health and RME Collaborative:\n\nACKNOWLEDGEMENT\n\nThis initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This session is supported by an independent medical education grant from AstraZeneca Pharmaceuticals.\n\nCREDIT AVAILABLE\n\nPhysicians — maximum of 1.0 AMA PRA Category 1 Credit™\n\nNurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)\n\nPharmacists — 1.0 Contact Hour (0.1 CEUs)\n\nAll other healthcare professionals completing this activity will be issued a statement of participation.\n\nTARGET AUDIENCE\n\nThis activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.\n\nLEARNING OBJECTIVES\n\nAssess the efficacy and safety of immunotherapies and combination therapy approaches for unresectable hepatocellular carcinoma (HCC)\n\nIntegrate clinical evidence and current guideline recommendations on immunotherapies and combination therapy into treatment plans for patients with unresectable HCC\n\nImplement interprofessional strategies for reducing disparities in care access and treatment for HCC in rural and underserved settings\n\nFACULTYGhassan K. Abou-Alfa, MD, MBA\n\nAttending Physician\n\nMemorial Sloan Kettering Cancer Center\n\nNew York, NY\n\nChris Prakash, MD\n\nDirector, Quality Services - Texas Oncology\n\nChair, Medical Oncology Quality - Texas Oncology\n\nPresident, Texas Society of Clinical Oncology\n\nMedical Director, Texas Oncology - Paris\n\nParis, TX\n\nJOINT ACCREDITATION STATEMENT\n\nIn support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.\n\nPHYSICIAN CONTINUING MEDICAL EDUCATION\n\nTalem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\n\nCONTINUING NURSING EDUCATION\n\nThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.\n\nCONTINUING PHARMACY EDUCATION\n\nTalem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.\n\n(Universal Activity Number – JA4008332-0000-24-032-L01-P)\n\nType of Activity: Application\n\nDISCLOSURE OF CONFLICTS OF INTERESTTalem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.\n\nAll relevant financial relationships have been mitigated.\n\nThe faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:\n\nFacultyGhassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Agenus, Inc., Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Inc., Genentech, Inc./Roche, Helsinn, Parker Institute for Cancer Immunotherapy, Pertzye - Digestive Care, Inc., Puma Biotechnology, Inc., QED Therapeutics, Servier Pharmaceuticals, and Yiviva; consultant/advisory board member for AbbVie, Inc., AstraZeneca Pharmaceuticals, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Inc., Exelixis, Inc., Genentech, Inc./Roche, Incyte Corporation, Ipsen, J-Pharma Co., Ltd., Merck & Co., Inc., Merus, Neogene Therapeutics, Novartis Pharmaceuticals Corporation, Servier Pharmaceuticals, Tempus, Vector Pharma, and Yiviva.\n\nChris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.\n\nPlanners, Managers, and Reviewer\n\nThe Talem Health planners, managers, and reviewer have nothing to disclose.\n\nDISCLOSURE OF UNLABELED USE\n\nThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.\n\nDISCLAIMER\n\nParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.\n\nCONTACT US\n\nFor questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 orcme@cmeruralhealth.com.\n\nMEDIA\n\nInternet activity\n\nCOMPUTER SYSTEM REQUIREMENTS\n\nSystem checker: Must meet all requirements of BroadcastMed Live Events Platform\n\nOperating system: Windows or Macintosh\n\nSupported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera\n\nHardware: computer, smartphone, or tablet\n\nBroadband Internet connection: high-speed connection preferable\n\nFEE INFORMATION\n\nThere is no fee for this educational activity."
    }
}